Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 8/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480232 | 0.91 | TRPV1 (0.62) | TRPV1GRIK1CNR1PTGER3MEN1 | |
| SCHEMBL6478899 | 0.90 | TRPV1 (0.59) | TRPV1GRIK1CNR1KDRPTGER3 | |
| SCHEMBL6490705 | 0.88 | TRPV1 (0.58) | TRPV1GRIK1CNR1PTGER3MEN1 | |
| SCHEMBL6488133 | 0.86 | CNR1 (0.64) | TRPV1GRIK1CNR1MEN1KMT2A | |
| SCHEMBL23831812 | 0.85 | TRPV1 (0.63) | TRPV1GRIK1PTGER3MEN1KMT2A | |
| SCHEMBL30792273 | 0.85 | TRPV1 (0.63) | TRPV1GRIK1PTGER3MEN1KMT2A | |
| SCHEMBL6489149 | 0.83 | TRPV1 (0.59) | TRPV1GRIK1CNR1KDRPTGER3 | |
| SCHEMBL6490134 | 0.82 | MGLL (0.65) | TRPV1GRIK1CNR1MEN1KMT2A | |
| SCHEMBL6478147 | 0.81 | TRPV1 (0.65) | TRPV1CNR1MEN1KMT2AALDH1A1 | |
| SCHEMBL6490717 | 0.80 | MAPT (0.56) | TRPV1CNR1KDRPTGER3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154230-A1 | Urea derivatives | BAYER HEALTHCARE AG (DE) | 2005-07-14 | — | — | US | claimed |
| US-20050154230-A1 | Urea derivatives | BAYER HEALTHCARE AG (DE) | 2005-07-14 | — | — | US | disclosed |
| EP-1461311-A2 | UREA DERIVATIVES AS VR1-ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003055848-A2 | UREA DERIVATIVES AS VR1- ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154230-A1 | Urea derivatives | SLC14A1, UBA1, VAT1 | TRPV1 214/4885GRIK1 84/4885CNR1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.